Goldman Sachs Group Inc. Buys 173,976 Shares of Relx Plc $RELX

Key Points

• Goldman Sachs Group Inc. increased its stake in RELX PLC by 4.5%, acquiring an additional 173,976 shares, bringing its total holdings to 4,072,342 shares valued at $205.3 million.
• RELX recently announced a semi-annual dividend of $0.2634 per share, which results in a yield of 170.0% and reflects a payout ratio of 28.49%.
• Shares of RELX have seen a 4.3% decline recently and currently sit near their 52-week low of $44.19, with analysts giving an average rating of "Buy" despite a recent downgrade by Wall Street Zen.

Goldman Sachs Group Inc. increased its stake in shares of Relx Plc (NYSE:RELX - Free Report) by 4.5% in the 1st quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 4,072,342 shares of the technology company's stock after buying an additional 173,976 shares during the quarter. Goldman Sachs Group Inc. owned 0.22% of Relx worth $205,287,000 at the end of the most recent quarter.

Several other large investors have also bought and sold shares of the stock. ABC Arbitrage SA grew its stake in shares of Relx by 40.1% in the 1st quarter. ABC Arbitrage SA now owns 194,197 shares of the technology company's stock worth $9,789,000 after acquiring an additional 55,579 shares in the last quarter. Charles Schwab Investment Management Inc. grew its position in Relx by 16.5% in the 1st quarter. Charles Schwab Investment Management Inc. now owns 167,175 shares of the technology company's stock worth $8,427,000 after purchasing an additional 23,692 shares in the last quarter. Pandora Wealth Inc. purchased a new stake in Relx in the 1st quarter valued at about $757,000. Massachusetts Financial Services Co. MA lifted its position in shares of Relx by 103.7% during the 1st quarter. Massachusetts Financial Services Co. MA now owns 106,220 shares of the technology company's stock worth $5,355,000 after buying an additional 54,062 shares in the last quarter. Finally, Cambridge Investment Research Advisors Inc. boosted its stake in shares of Relx by 19.5% in the 1st quarter. Cambridge Investment Research Advisors Inc. now owns 18,957 shares of the technology company's stock worth $956,000 after buying an additional 3,092 shares during the last quarter. 15.02% of the stock is currently owned by institutional investors.

Wall Street Analyst Weigh In

Separately, Wall Street Zen downgraded Relx from a "buy" rating to a "hold" rating in a research report on Friday, September 5th. One research analyst has rated the stock with a Strong Buy rating and four have assigned a Buy rating to the company's stock. Based on data from MarketBeat.com, the stock has an average rating of "Buy".

Relx Stock Performance

Shares of NYSE RELX traded up $0.20 during trading on Friday, reaching $46.53. 1,045,264 shares of the stock traded hands, compared to its average volume of 1,532,953. The company has a debt-to-equity ratio of 2.55, a current ratio of 0.47 and a quick ratio of 0.42. The stock has a market capitalization of $85.36 billion, a P/E ratio of 25.02, a price-to-earnings-growth ratio of 3.02 and a beta of 0.87. Relx Plc has a 52-week low of $44.19 and a 52-week high of $56.33. The company has a 50-day moving average of $49.80 and a 200-day moving average of $51.11.

Relx Cuts Dividend

The firm also recently announced a semi-annual dividend, which will be paid on Tuesday, September 16th. Shareholders of record on Friday, August 8th will be given a dividend of $0.2634 per share. This represents a yield of 170.0%. The ex-dividend date is Friday, August 8th. Relx's dividend payout ratio (DPR) is currently 28.49%.

Relx Profile

RELX Plc engages in provision of information and analytics solutions for professional and business customers across industries. It operates through the following business segments: Scientific, Technical & Medical; Risk & Business Analytics; Legal; and Exhibitions. The Scientific, Technical & Medical segment is a global information analytics business that helps institutions and professionals advance healthcare, open science, and improve performance for the benefit of humanity.